Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

March 17, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Gorlin Syndrome
Interventions
DRUG

Patidegib Topical Gel

Patidegib Gel 2% is a smooth, clear, colorless-to-yellow, viscous, hydro-alcoholic gel for topical administration.

DRUG

Patidegib Topical Gel with no active patidegib

Vehicle Gel consists of the excipients of Patidegib Gel with no active patidegib. It is a smooth viscous gel for topical administration.

Trial Locations (40)

10065

Memorial Sloan Kettering Cancer Center, New York

17033

Penn State Hershey Medical Center, Hershey

27710

Duke University Health System, Durham

32308

Dermatology Associates of Tallahassee, Tallahassee

33612

University of South Florida Health, Tampa

44124

Apex Clinical Research Center, Mayfield Heights

44195

Cleveland Clinic - Main Campus, Cleveland

44718

Apex Clinical Research Center, Canton

48109

University of Michigan Health - Michigan Medicine - University Hospital, Ann Arbor

55112

Minnesota Clinical Study Center, New Brighton

60637

The University of Chicago Medicine, Chicago

64506

MediSearch Clinical Trials, Saint Joseph

72758

Northwest Arkansas Clinical Trials Center, Rogers

73102

SSM Health Dermatology, Oklahoma City

75034

North Texas Center for Clinical Research, Frisco

77030

The University of Texas MD Anderson Cancer Center, Houston

90024

University of California Los Angeles (UCLA) - Center for Inflammatory Bowel Diseases - Westwood Location, Los Angeles

92660

The Dermatology Center of Newport, Newport Beach

94063

Stanford University - Lucille Packard's Children's Hospital, Redwood City

94538

Center for Dermatology Clinical Research, Fremont

97239

Oregon Health and Science University, Portland

06519

Yale University, New Haven

21287-0006

The Johns Hopkins Hospital, Baltimore

07044

Schweiger Dermatology P.C., Verona

Unknown

Hopital Avicenne, Bobigny

Centre Hospitalier Universitaire De Nantes, Nantes

Centre Hospitalier Lyon Sud, Pierre-Bénite

Ludwig-Maximilians-Universitaet Muenchen (LMU) - Klinik und Poliklinik fuer Dermatologie und Allergologie, Munich

Charité Universitätsmedizin Berlin - Campus Charité Mitte, Berlin

DRK Gemeinnützige Krankenhaus GmbH Sachsen, Chemnitz

ASST Spedali Civili di Brescia, Brescia

AOU Maggiore della Carita, Novara

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome

Maastricht University Medical Center, Maastricht

Hospital Clinic Barcelona, Barcelona

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Universitartio 12 De Octubre, Madrid

The University of Birmingham, Birmingham

Barts Health NHS Trust - The Royal London Hospital, London

Northern Care Alliance NHS Foundation Trust, Salford

All Listed Sponsors
lead

Sol-Gel Technologies, Ltd.

INDUSTRY

NCT06050122 - Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome | Biotech Hunter | Biotech Hunter